TQB3122

TQB3122 is an orally bioavailable small molecule inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) developed by Chia Tai Tianqing Pharmaceutical Group. It functions by inhibiting the PARP enzyme, which is critical for the repair of single-strand DNA breaks via the base excision repair pathway. In tumors with homologous recombination deficiencies (HRD), such as those with BRCA1 or BRCA2 mutations, the inhibition of PARP1 leads to the accumulation of unrepaired DNA damage and subsequent double-strand breaks, resulting in "synthetic lethality" and tumor cell death. TQB3122 is currently being investigated in Phase I clinical trials for patients with advanced solid tumors, specifically targeting ovarian, fallopian tube, primary peritoneal, breast, and prostate cancers.